New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
07:04 EDTTHRXFDA panel vote on olodaterol positive for Theravance drug, says Piper Jaffray
Piper Jaffray believes the positive FDA panel recommendation for Boehringer's olodaterol in COPD signals a similar outcome for Theravance's Breo's panel on March 7. The firm recommends buying shares of Theravance ahead of the FDA panel and keeps an Overweight rating on the name with a $32 price target.
News For THRX From The Last 14 Days
Check below for free stories on THRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
08:49 EDTTHRXGSK, Theravance announce Phase III study of FF/VI in Japan
Subscribe for More Information
08:37 EDTTHRXTheravance, GlaxoSmithKline receive Australian approval for Breo Ellipta
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the Therapeutic Goods Administration has approved BREO ELLIPTA for the treatment of patients with asthma or chronic obstructive pulmonary disease, or COPD, in Australia. Two strengths of BREO ELLIPTA have been licensed for the treatment of asthma and one strength has been licensed for the treatment of COPD.
April 10, 2014
16:13 EDTTHRXTheravance announces Phase 2b study initiated with TD-4208 in COPD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use